Resources from the same session
LBA47 - Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)
Presenter: Alexander Stratigos
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1077MO - PD1 blockade with pembrolizumab in classic and endemic Kaposi sarcoma: A multicenter phase II study
Presenter: Julie Delyon
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1078MO - MIND-DC: A randomized phase III trial to assess the efficacy of adjuvant dendritic cell vaccination in comparison to placebo in stage IIIB and IIIC melanoma patients
Presenter: Kalijn Bol
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1079MO - Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES)
Presenter: Peter Lau
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1080MO - The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition
Presenter: Judith Versluis
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1081MO - Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
Presenter: Anna Di Giacomo
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA48 - Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial
Presenter: Inge-Marie Svane
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1082MO - 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone
Presenter: Caroline Robert
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1083MO - Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma
Presenter: Cara Haymaker
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Ana Maria Arance Fernandez
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Slides
Webcast